X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Data support ACE1702 as off-the-shelf natural killer (NK) cell therapy against HER2-expressing cancers. ACE1702 overcomes limitations of current cancer cell therapies by enhancing the innate ability of NK cells to target and destroy HER2-expressing tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DBPR115
Therapeutic Area: Oncology Product Name: DBPR115
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
